TRVI Valuation

Trevi Therapeutics Inc

Add to Watchlist

Advanced Chart

7.150

-0.12(-1.651%)1D

Overview
Forecast
Valuation
Earnings

TRVI Relative Valuation

TRVI's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, TRVI is overvalued; if below, it's undervalued.

Historical Valuation

Trevi Therapeutics Inc (TRVI) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.35. The fair price of Trevi Therapeutics Inc (TRVI) is between to according to relative valuation methord.

Relative Value

Fair Zone

Current Price：7.30

Fair

-15.67

Trailing

Forward

-10.33

EV/EBITDA

Trevi Therapeutics Inc. (TRVI) has a current EV/EBITDA of -10.33. The 5-year average EV/EBITDA is -1.96. The thresholds are as follows: Strongly Undervalued below -7.29, Undervalued between -7.29 and -4.63, Fairly Valued between 0.70 and -4.63, Overvalued between 0.70 and 3.36, and Strongly Overvalued above 3.36. The current Forward EV/EBITDA of -10.33 falls within the Strongly Undervalued range.

-9.12

EV/EBIT

Trevi Therapeutics Inc. (TRVI) has a current EV/EBIT of -9.12. The 5-year average EV/EBIT is -1.99. The thresholds are as follows: Strongly Undervalued below -6.88, Undervalued between -6.88 and -4.43, Fairly Valued between 0.45 and -4.43, Overvalued between 0.45 and 2.90, and Strongly Overvalued above 2.90. The current Forward EV/EBIT of -9.12 falls within the Strongly Undervalued range.

0.00

Trevi Therapeutics Inc. (TRVI) has a current PS of 0.00. The 5-year average PS is 0.00. The thresholds are as follows: Strongly Undervalued below 0.00, Undervalued between 0.00 and 0.00, Fairly Valued between 0.00 and 0.00, Overvalued between 0.00 and 0.00, and Strongly Overvalued above 0.00. The current Forward PS of 0.00 falls within the Strongly Undervalued range.

-14.73

P/OCF

Trevi Therapeutics Inc. (TRVI) has a current P/OCF of -14.73. The 5-year average P/OCF is -3.40. The thresholds are as follows: Strongly Undervalued below -9.78, Undervalued between -9.78 and -6.59, Fairly Valued between -0.21 and -6.59, Overvalued between -0.21 and 2.98, and Strongly Overvalued above 2.98. The current Forward P/OCF of -14.73 falls within the Strongly Undervalued range.

-13.02

P/FCF

Trevi Therapeutics Inc. (TRVI) has a current P/FCF of -13.02. The 5-year average P/FCF is -2.94. The thresholds are as follows: Strongly Undervalued below -9.42, Undervalued between -9.42 and -6.18, Fairly Valued between 0.30 and -6.18, Overvalued between 0.30 and 3.53, and Strongly Overvalued above 3.53. The current Forward P/FCF of -13.02 falls within the Strongly Undervalued range.

Trevi Therapeutics Inc (TRVI) has a current Price-to-Book (P/B) ratio of 4.46. Compared to its 3-year average P/B ratio of 2.78 , the current P/B ratio is approximately 60.60% higher. Relative to its 5-year average P/B ratio of 2.70, the current P/B ratio is about 65.13% higher. Trevi Therapeutics Inc (TRVI) has a Forward Free Cash Flow (FCF) yield of approximately -4.83%. Compared to its 3-year average FCF yield of -18.69%, the current FCF yield is approximately -74.15% lower. Relative to its 5-year average FCF yield of -40.29% , the current FCF yield is about -88.01% lower.

4.46

P/B

Median3y

2.78

Median5y

2.70

-4.83

FCF Yield

Median3y

-18.69

Median5y

-40.29

Competitors Valuation Multiple

The average P/S ratio for TRVI's competitors is 77.74, providing a benchmark for relative valuation. Trevi Therapeutics Inc Corp (TRVI) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

TRVI.O

Trevi Therapeutics Inc

Anavex Life Sciences Corp

Loss

814.27M

Performance Decomposition

Market capitalization of TRVI increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of TRVI in the past 1 year is driven by Unknown.